AUD 0.0
(0.0%)
Year | Total Assets | Total Assets Growth |
---|---|---|
2024 | 4.16 Million AUD | -44.69% |
2023 | 7.52 Million AUD | -46.14% |
2022 | 13.96 Million AUD | 8.36% |
2021 | 12.89 Million AUD | 139.79% |
2020 | 5.37 Million AUD | -32.23% |
2019 | 7.93 Million AUD | -0.49% |
2018 | 7.97 Million AUD | 152.43% |
2017 | 3.15 Million AUD | -25.83% |
2016 | 4.25 Million AUD | -10.77% |
2015 | 4.77 Million AUD | -67.78% |
2014 | 14.81 Million AUD | 24.97% |
2013 | 11.85 Million AUD | -11.29% |
2012 | 13.36 Million AUD | -10.0% |
2011 | 14.84 Million AUD | -8.96% |
2010 | 16.3 Million AUD | -14.97% |
2009 | 19.17 Million AUD | -19.62% |
2008 | 23.85 Million AUD | 2813.74% |
2007 | 818.81 Thousand AUD | 0.0% |
Year | Total Assets | Total Assets Growth |
---|---|---|
2024 Q2 | 5.6 Million AUD | 0.0% |
2024 FY | 4.16 Million AUD | -44.69% |
2024 Q4 | 4.16 Million AUD | 0.0% |
2023 Q4 | 7.52 Million AUD | 0.0% |
2023 FY | 7.52 Million AUD | -46.14% |
2023 Q2 | 11.54 Million AUD | 0.0% |
2022 Q4 | 13.96 Million AUD | 0.0% |
2022 FY | 13.96 Million AUD | 8.36% |
2022 Q2 | 19.05 Million AUD | 0.0% |
2021 FY | 12.89 Million AUD | 139.79% |
2021 Q2 | 14.54 Million AUD | 0.0% |
2021 Q4 | 12.89 Million AUD | 0.0% |
2020 Q2 | 6.32 Million AUD | 0.0% |
2020 FY | 5.37 Million AUD | -32.23% |
2020 Q4 | 5.37 Million AUD | 0.0% |
2019 Q4 | 7.93 Million AUD | 0.0% |
2019 FY | 7.93 Million AUD | -0.49% |
2019 Q2 | 8.94 Million AUD | 0.0% |
2018 FY | 7.97 Million AUD | 152.43% |
2018 Q2 | 2.27 Million AUD | 0.0% |
2018 Q4 | 7.97 Million AUD | 0.0% |
2017 Q4 | 3.15 Million AUD | 0.0% |
2017 FY | 3.15 Million AUD | -25.83% |
2017 Q2 | 3.77 Million AUD | 0.0% |
2016 FY | 4.25 Million AUD | -10.77% |
2016 Q4 | 4.25 Million AUD | 0.0% |
2016 Q2 | 4.11 Million AUD | 0.0% |
2015 Q2 | 11.31 Million AUD | 0.0% |
2015 FY | 4.77 Million AUD | -67.78% |
2015 Q4 | 4.77 Million AUD | 0.0% |
2014 FY | 14.81 Million AUD | 24.97% |
2014 Q4 | 14.81 Million AUD | 0.0% |
2014 Q2 | 16.65 Million AUD | 0.0% |
2013 Q3 | 11.85 Million AUD | -14.2% |
2013 FY | 11.85 Million AUD | -11.29% |
2013 Q4 | 11.85 Million AUD | 0.0% |
2013 Q1 | 13.81 Million AUD | 3.39% |
2013 Q2 | 13.81 Million AUD | 0.0% |
2012 Q4 | 13.36 Million AUD | 0.0% |
2012 FY | 13.36 Million AUD | -10.0% |
2011 Q4 | 14.84 Million AUD | 0.0% |
2011 FY | 14.84 Million AUD | -8.96% |
2010 Q4 | 16.3 Million AUD | 0.0% |
2010 FY | 16.3 Million AUD | -14.97% |
2009 Q4 | 19.17 Million AUD | 0.0% |
2009 FY | 19.17 Million AUD | -19.62% |
2008 Q4 | 23.85 Million AUD | 0.0% |
2008 FY | 23.85 Million AUD | 2813.74% |
2007 FY | 818.81 Thousand AUD | 0.0% |
Name | Total Assets | Total Assets Difference |
---|---|---|
AdAlta Limited | 5.57 Million AUD | 25.326% |
Acrux Limited | 8.96 Million AUD | 53.569% |
Amplia Therapeutics Limited | 14.84 Million AUD | 71.967% |
Biome Australia Limited | 8.27 Million AUD | 49.72% |
BTC Health Limited | 5.14 Million AUD | 19.174% |
Chimeric Therapeutics Limited | 15.27 Million AUD | 72.752% |
CSL Limited | 56.93 Billion AUD | 99.993% |
Clarity Pharmaceuticals Ltd | 154.62 Million AUD | 97.309% |
Clinuvel Pharmaceuticals Limited | 231.12 Million AUD | 98.199% |
Noxopharm Limited | 6.78 Million AUD | 38.654% |
PharmAust Limited | 11.12 Million AUD | 62.592% |
Proteomics International Laboratories Limited | 10.87 Million AUD | 61.733% |
Prescient Therapeutics Limited | 20.39 Million AUD | 79.593% |
PYC Therapeutics Limited | 91.23 Million AUD | 95.439% |
Race Oncology Limited | 20.22 Million AUD | 79.427% |
Starpharma Holdings Limited | 36.81 Million AUD | 88.696% |
EZZ Life Science Holdings Limited | 25.55 Million AUD | 83.713% |
Botanix Pharmaceuticals Limited | 112.46 Million AUD | 96.3% |
Memphasys Limited | 12.43 Million AUD | 66.52% |
Nyrada Inc. | 5.9 Million AUD | 29.551% |
Anatara Lifesciences Ltd | 1.67 Million AUD | -148.984% |
Telix Pharmaceuticals Limited | 398.3 Million AUD | 98.955% |
Bio-Gene Technology Limited | 3.15 Million AUD | -31.713% |
Zelira Therapeutics Limited | 5.18 Million AUD | 19.714% |
Dimerix Limited | 32.07 Million AUD | 87.027% |
Neuren Pharmaceuticals Limited | 247.97 Million AUD | 98.322% |
Orthocell Limited | 26.61 Million AUD | 84.364% |
Imugene Limited | 151.39 Million AUD | 97.251% |
Cynata Therapeutics Limited | 8.38 Million AUD | 50.388% |
Immutep Limited | 147.44 Million AUD | 97.178% |
Arovella Therapeutics Limited | 13.28 Million AUD | 68.674% |
Alterity Therapeutics Limited | 19.22 Million AUD | 78.352% |
Nanollose Limited | 241.95 Thousand AUD | -1620.009% |
Invex Therapeutics Ltd | 6.12 Million AUD | 32.001% |
NeuroScientific Biopharmaceuticals Limited | 5.43 Million AUD | 23.442% |
Island Pharmaceuticals Limited | 2.56 Million AUD | -62.278% |
Biotron Limited | 493.47 Thousand AUD | -743.32% |
Radiopharm Theranostics Limited | 72.03 Million AUD | 94.223% |
Tissue Repair Ltd | 19.38 Million AUD | 78.537% |
AnteoTech Limited | 9.38 Million AUD | 55.639% |
Hexima Limited | 2.26 Million AUD | -83.41% |
Paradigm Biopharmaceuticals Limited | 27.39 Million AUD | 84.806% |
Recce Pharmaceuticals Ltd | 6.36 Million AUD | 34.665% |
Avecho Biotechnology Limited | 7.31 Million AUD | 43.142% |
Actinogen Medical Limited | 21.31 Million AUD | 80.473% |
Immuron Limited | 15.54 Million AUD | 73.237% |
Argenica Therapeutics Limited | 16.37 Million AUD | 74.59% |